Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR6 | O00574 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | GPR6 | P46095 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9970059 | 0.95 | CXCR6 (0.46) | CXCR6SMN1; SMN2NPC1RAB9ATP53 | |
| Trifluoroacetic Acid SCHEMBL2067600 | 0.94 | MCHR1 (0.47) | CXCR6SMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL9970038 | 0.89 | MCHR1 (0.51) | CXCR6SMN1; SMN2NPC1RAB9ATP53 | |
| Trifluoroacetic Acid SCHEMBL2067634 | 0.88 | HTR2B (0.49) | SMN1; SMN2NPC1RAB9AHTR2B | |
| Trifluoroacetic Acid SCHEMBL2068008 | 0.88 | NPC1 (0.49) | SMN1; SMN2NPC1RAB9AMCHR1TSHR | |
| Trifluoroacetic Acid SCHEMBL2066884 | 0.86 | EPHX2 (0.45) | HTR2B | |
| SCHEMBL18536508 | 0.83 | HTR2B (0.41) | HTR2B | |
| SCHEMBL2067359 | 0.83 | HTR2B (0.41) | HTR2B | |
| Trifluoroacetic Acid SCHEMBL2068117 | 0.83 | NPC1 (0.46) | NPC1RAB9AHTR2BGPR6 | |
| SCHEMBL9970053 | 0.82 | HTR2B (0.55) | SMN1; SMN2NPC1RAB9AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170860-B9 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2170860-B1 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8431597-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2012-06-21 | — | — | US | disclosed |
| US-8148401-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | CXCR6 2903/4885SMN1; SMN2 1764/4885NPC1 2444/4885 |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | CXCR6 2903/4885SMN1; SMN2 1764/4885NPC1 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.